Article
Medicine, General & Internal
Masashi Uehara, Yukio Nakamura, Takako Suzuki, Masaki Nakano, Jun Takahashi
Summary: This study compared the efficacy and safety of ibandronate and zoledronic acid in Japanese postmenopausal osteoporotic patients, finding that both drugs significantly and safely improved bone turnover markers and BMD during 30 months of treatment. The ZOL group tended to exhibit greater gains in BMD compared to the IBN group, warranting further investigation.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Medicine, General & Internal
Shih-Yin Lin, Min-Chih Hung, Shih-Fu Chang, Fon-Yih Tsuang, Jenny Zwei-Chieng Chang, Jui-Sheng Sun
Summary: This network meta-analysis study compared the efficacy and safety of different drugs for the treatment of postmenopausal osteoporosis. Results showed that strontium ranelate, fluoride, and hormone replacement therapy were most effective in increasing bone mineral density, while parathyroid hormone was most effective in preventing new hip fractures. Bisphosphonate, monoclonal antibody, and fluoride had balanced efficacy in increasing BMD at all sites, with monoclonal antibody, bisphosphonate, and PTH being more favorable for overall effectiveness in increasing BMD and preventing hip fractures.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Saba Tariq, Sundus Tariq, Shahad Abduljalil Abualhamael, Muhammad Shahzad
Summary: This study aimed to investigate the changes in circulating chemerin, vaspin, omentin-1, and osteoprotegerin levels after treatment with oral ibandronate in postmenopausal osteoporotic females. The results showed a significant decrease in chemerin levels, as well as a significant increase in vaspin and osteoprotegerin levels after 6 months of ibandronate treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Gianmaria Salvio, Alessandro Ciarloni, Claudio Gianfelice, Francesca Lacche, Sofia Sabatelli, Gilberta Giacchetti, Giancarlo Balercia
Summary: Polyphenols have no significant effects on bone mineral density in postmenopausal women, but they may have a positive impact on lumbar spine BMD in studies with a duration of 24 months or longer. Additionally, polyphenols can slightly increase bone-specific alkaline phosphatase levels and decrease pyridinoline levels.
Review
Endocrinology & Metabolism
S. Singh, S. Dutta, S. Khasbage, T. Kumar, J. Sachin, J. Sharma, S. B. Varthya
Summary: The study illustrates the significant effect of Romosozumab in reducing fractures and falls, as well as increasing bone mineral density in postmenopausal osteoporosis patients. The results suggest that Romosozumab treatment may be recommended for this patient population based on evidence of efficacy and safety.
OSTEOPOROSIS INTERNATIONAL
(2022)
Review
Endocrinology & Metabolism
Hongyan Liu, Guoqi Wang, Ting Wu, Yiming Mu, Weijun Gu
Summary: This meta-analysis found that the use of ED-71 could improve bone mineral density (BMD) and fractures at various sites, especially compared with alfacalcidol or a combination with bisphosphonate for patients with osteoporosis. However, the use of ED-71 was associated with an increased risk of increased urine calcium level.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Nanae Ogata, Uhi Toh, Tomoya Sudou, Suguru Ogata, Yuko Takao, Rie Sugihara, Hideaki Watanabe, Shuntaro Matushima, Yoshito Akagi
Summary: This study evaluated the efficacy and safety of oral bisphosphonate minodronate in preventing bone loss complications in post-menopausal breast cancer patients. The results showed that the combined administration of minodronate and aromatase inhibitors was safe and effective in preventing bone loss complications.
ANTICANCER RESEARCH
(2022)
Review
Endocrinology & Metabolism
Alexander H. Seeto, Bo Abrahamsen, Peter R. Ebeling, Alexander J. Rodriguez
Summary: The study evaluated the cardiovascular safety of denosumab through a systematic review of randomized controlled trials. It found that postmenopausal women treated with denosumab had a higher risk of cardiovascular adverse events compared to those treated with bisphosphonates, but no significant difference was observed compared to placebo. Future trials should focus on standardized reporting of cardiovascular adverse events to better understand the effects of bone active medications.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Article
Endocrinology & Metabolism
Tomonori Kobayakawa, Akiko Miyazaki, Jun Takahashi, Yukio Nakamura
Summary: This study compared the efficacy of ibandronate and denosumab as sequential therapy after romosozumab treatment and found that denosumab was more effective in increasing lumbar spine bone density than ibandronate. Both treatments showed favorable trends in total hip and femoral neck bone density. Serum bone turnover markers were significantly reduced in both groups. Some minor adverse events occurred in both groups.
Review
Public, Environmental & Occupational Health
Ming-ling Ma, Zi-jian Ma, Yi-lang He, Hao Sun, Bin Yang, Bin-jia Ruan, Wan-da Zhan, Shi-xuan Li, Hui Dong, Yong-xiang Wang
Summary: The meta-analysis indicates that VK2 supplementation has a positive effect on maintaining and improving lumbar spine bone mineral density in postmenopausal women, while also reducing fracture incidence, serum uc-OC levels, and the ratio of uc-OC to cOC.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Plant Sciences
Chung-Yu Huang, Ciao-Jhih Cheng, Wen-Fei Chiou, Wei-Chiao Chang, Yi-No Kang, Mei-Hsien Lee
Summary: The systematic review and meta-analysis of 17 randomized controlled trials showed that adding Duhuo Jisheng Decoction (DHJSD) to bisphosphonate medications in the treatment of osteoporosis resulted in higher efficacy rates, increased lumbar BMD, reduced pain scores, and lower overall adverse event rates.
JOURNAL OF ETHNOPHARMACOLOGY
(2022)
Review
Multidisciplinary Sciences
Zhi-Ming Liu, Min Zhang, Yuan Zong, Ding Zhang, Zhu-Bin Shen, Xiao-Qing Guan, Fei Yin
Summary: This study aimed to compare the efficacy of alendronate and teriparatide in the treatment of glucocorticoid-induced osteoporosis. The study found that compared to alendronate, teriparatide could reduce the rate of new vertebral fractures and increase the bone mineral density of the lumbar spine, femoral neck, and total hip. There was no significant difference in the incidence of non-vertebral fractures and adverse events between the two groups.
Review
Medicine, General & Internal
Fanglian Lou, Siping Xian, ZhongJun Shu, Zhouhai Zheng
Summary: This study systematically investigated the efficacy and safety of Xianling Gubao capsule in the treatment of postmenopausal osteoporosis, assessing outcomes such as total effective rate, bone density, blood calcium and phosphorus levels, pain score, and quality of life. The results provide reliable evidence-based support for the clinical application of Xianling Gubao capsule in treating postmenopausal osteoporosis.
Review
Endocrinology & Metabolism
Regina Dantas Jales de Oliveira, Raphael Goncalves de Oliveira, Lais Campos de Oliveira, Sebastiao David Santos-Filho, Danubia Cunha Sa-Caputo, Mario Bernardo-Filho
Summary: This study observed significant effects of whole-body vibration (WBV) on bone mineral density (BMD) in postmenopausal women, with high-quality evidence for high-frequency, low-magnitude, and high-cumulative-dose use. The updated systematic review and meta-analysis found that WBV with high frequency (approximately 30 Hz), low magnitude (approximately 0.3 g), and high cumulative dose (approximately 7000 min) can improve lumbar spine BMD in postmenopausal women.
OSTEOPOROSIS INTERNATIONAL
(2023)
Review
Medicine, General & Internal
Kemeng Xiang, Jingfan Yang, Weitong Liu, Limin Chen, Huiming Hou, Xing Zhou, Jinlei Li
Summary: This study aims to evaluate the efficacy and safety of the traditional Chinese medicine prescription Buzhong Yiqi Decoction (BZYQD) in the management of postmenopausal osteoporosis (PMOP), providing high-quality evidence-based clinical recommendations.
